The market taxonomy for hemoperfusion apparatus is further disaggregated by cartridge type, a dimension that shapes procurement cycles, pricing strategy and regulatory pathways. Activated carbon devices still constitute the largest installed base (>55 % of 2023 revenues) owing to their broad-spectrum adsorption, low manufacturing cost and well-documented efficacy in mycotoxin and barbiturate removal; however, growth is decelerating (CAGR 2–3 %) as clinicians shift toward more selective media. Resin-based cartridges—using neutral polystyrene divinyl-benzene beads—claim ~28 % share and are expanding at mid-single-digit rates, spurred by superior biocompatibility and higher affinity for hydrophobic cytokines, making them the default choice in ICU settings. Immunoadsorption columns, though holding only ~12 % of the market, generate the highest per-unit revenue (>USD 700) because they incorporate protein-A or antigen-coated matrices for selective antibody removal in transplant desensitization and neuromuscular disorders; hospital tenders are episodic but carry large order values. A residual 5 % is captured by hybrid or surface-modified devices (e.g., carbon-resin composites, heparin-grafted carriers) that attempt to balance selectivity and capacity; volumes remain niche but are watched closely by manufacturers seeking next-generation platforms.
